Linda Burkly, Ph.D., was 37 years into a career at Biogen when Editas Medicines CEO Gilmore O’Neill—himself an alum of the ...
The FDA needs a few more weeks to decide the fate of Moderna's RSV vaccine, the company announced. A decision is now slated ...
About 100 days after implanting its first human participant with its brain-computer interface chip, Neuralink reported that ...
The need to stretch strained bank balances has hit pipelines once again. | The need to stretch strained bank balances has hit ...
Innovent has scored another phase 3 win for mazdutide as the drug showed its superiority to Eli Lilly's diabetes and heart ...
In its ongoing mission to find the next Wegovy, Novo Nordisk has penned another partnership to seek out next-gen obesity ...
J&J's Megadyne division pulls pediatric electrosurgery pad from market following patient burn recall
One of Johnson & Johnson’s medical device subsidiaries is pulling one of its pediatric electrosurgery devices from the market ...
It appears that Sanofi’s loss is Shionogi’s gain. Five months after the Federal Trade Commission scuttled Sanofi’s attempt to ...
Sanofi's CSO has left the company amid a global R&D restructuring. Pfizer tags longtime Citi analyst for C-suite-level ...
The FDA is alerting users and providers to Tandem Diabetes Care’s recall of its insulin pump-controlling iPhone app after a ...
Following 12 company recalls and nearly 3,000 reported issues related to its cardiovascular life support systems since ...
MacroGenics’ safety woes have followed into phase 2. Having dialed down the dose in response to early-phase data, the biotech ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results